生脉注射液联合化疗治疗晚期肺癌的临床观察

Clinical observation of shengmai injection combined chemotherapy in advanced lung cancer

目的:观察生脉注射液联合化疗与单纯化疗治疗晚期非小细胞肺癌的近期疗效及对生活质量和化疗毒副反应的作用。方法:将64例晚期非小细胞肺癌患者随机分为治疗组32例和对照组32例。治疗组采用NP方案化疗,并在化疗第1天开始用生脉注射液60ml加入5%GS250ml中静脉滴注,连用10天;对照组单用化疗,方案同治疗组,21天为1周期,疗程为2周期。结果:治疗组近期有效率为46.9%,对照组为40.6%,近期疗效无显著性差异(P>0.05);KPS评分改善的患者在治疗组高于对照组(59.4%vs34.4%,P<0.05);治疗组白细胞下降(≥Ⅱ度)及恶心呕吐反应(≥Ⅱ度)的患者明显低于对照组(P<0.05)。结论:生脉注射液联合化疗可以减轻晚期非小细胞肺癌患者的化疗毒副反应,提高对化疗的耐受能力,改善生活质量。

Objective：To observe and evaluate the effect of Shengmai Injection combined chemotherapy in advanced non - small cell lung cancer（ NSCLC）. Methods：Sixty four patients were divided randomly into control group and treatment group . The treatment group accepted 60 ml Shengmai Injection and 250 ml glucose infusion intravenously from the first day with chemotherapy for 10 days. Patients in the control group accepted chemotherapy only,21 days were one cycle . All patients received chemotherapy for two cycles. Results： The overall response rate of treatment group and control group were 46.9% and 40.6% respectively, there was no significant difference between the two group （ P 〉 0.05 ） ; The score of KPS incereased in treatment group （59.4% vs 34.4%, P 〈 0.05 ） ; Degree of leukocyte decreased, nausea and vomiting reaction in treatment groupn was lessobviously than control group（P〈0.05）. Conclusion：Shengmai Injection can decrease toxic reaction, increase tolerance of chemotherapy and improve quality of life for advanced NSCLC.